Single Cell Genomics of Psoriatic Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-01

Study Completion Date

2020-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunologic Response to Secukinumab in Plaque Psoriasis

NCT02592018

Psoriasis

COMPLETED PHASE4

Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis

NCT06055699

Psoriasis Microbial Colonization

NOT_YET_RECRUITING

Study of Psoriatic Arthritis

NCT00001420

Psoriasis Psoriatic Arthritis

COMPLETED

An Exploratory Genetic Study in Participants With Psoriasis

NCT02155192

Psoriasis

COMPLETED

Characterization of the Fungal Immunopeptidome Involved in the Immunopathological Mechanisms of Psoriasis

NCT06610942

Psoriasis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

10 HLA-Cw6+

HLA-Cw6+ patients will donate blood and skin samples

Group Type EXPERIMENTAL

Skin biopsy

Intervention Type PROCEDURE

Four 4-5 mm punch biopsies of the skin

Blood draw

Intervention Type PROCEDURE

Blood will be drawn to test for HLA-cw6 status

10 HLA Cw6-

HLA-Cw6- patients will donate blood and skin samples

Group Type EXPERIMENTAL

Skin biopsy

Intervention Type PROCEDURE

Four 4-5 mm punch biopsies of the skin

Blood draw

Intervention Type PROCEDURE

Blood will be drawn to test for HLA-cw6 status

Healthy Skin

Healthy patients will donate blood and skin samples

Group Type EXPERIMENTAL

Skin biopsy

Intervention Type PROCEDURE

Four 4-5 mm punch biopsies of the skin

Blood draw

Intervention Type PROCEDURE

Blood will be drawn to test for HLA-cw6 status

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin biopsy

Four 4-5 mm punch biopsies of the skin

Intervention Type PROCEDURE

Blood draw

Blood will be drawn to test for HLA-cw6 status

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For subjects in the psoriasis group:

1. Ability to provide written consent and comply with the protocol
2. At least 18 years of age
3. Diagnosis of plaque psoriasis for at least 6 months prior to enrollment
4. BSA \> 5% and at least one target plaque on trunk or extremities greater than 10cm2

For control subjects:

1. Ability to provide written consent and comply with the protocol
2. At least 18 years of age
3. No previous diagnosis of psoriasis or other inflammatory skin conditions

Exclusion Criteria

For subjects in the psoriasis group:

1. Subject has non-plaque form of psoriasis.
2. Subject has drug-induced psoriasis.
3. Pregnancy at any point during the study period.
4. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents.
5. Known HIV positive status.
6. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
7. Known coagulopathy.

For control subjects:

1. Any physical examination findings by the investigators consistent with psoriasis or other inflammatory skin conditions.
2. Pregnancy at any point during the study period.
3. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents.
4. Known HIV positive status.
5. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
6. Known coagulopathy.
7. Use of any immunosuppressant or immunomodulating therapies within 6 months.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes